Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled phase2b study of Ustekinumab in patients with moderately to severely active Crohnʼs disease
2011 ◽
Vol 17
◽
pp. S24
◽
Keyword(s):